Lymphokine, monoclonal antibody specific to the lymphokine and t

Details Lymphokine, monoclonal antibody specific to the lymphokine and t Lymphokine, monoclonal antibody specific to the lymphokine and t

1984-11-27

1988-07-19

Hazel, Blondel

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530351, 435 68, 4351722, A61K 3700, C07K 1514, C12P 2100, C12N 1500

Patent

active

047585498

ABSTRACT:
Disclosed is an invention relating to a novel lymphokine and to the production and uses thereof. The invention also relates to a monoclonal antibody specific to the lymphokine and its production. The novel lymphokine is a glycoprotein having a molecular weight of 20,000.+-.2,000 daltons; isoelectric point pI, 5.6.+-.0.2; electrophoretic mobility Rf, 0.29.+-.0.02; and cytotoxic on a mouse cell line L 929. The lymphokine inhibits significantly the growth of malignant human tumors in vivo. The monoclonal antibody is IgM or IgG class, and neutralizes specifically the cytotoxic activity of the lymphokine.

REFERENCES:
patent: 4438032 (1984-03-01), Golde et al.
patent: 4481137 (1984-11-01), Ohneshi et al.
patent: 4495282 (1985-01-01), Ohneshi et al.

Affiliated with

Also associated with

Rating

Lymphokine, monoclonal antibody specific to the lymphokine and t does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lymphokine, monoclonal antibody specific to the lymphokine and t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphokine, monoclonal antibody specific to the lymphokine and t will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-597287